Jean Sévigny
Chercheur universitaire
Axe Maladies infectieuses et immunitaires
Immunologie appliquée
Immunologie humorale et immunochimie
Immunité innée
Maladies auto-immunes
Immunologie
Enzymes
Biochimie
Prolifération, différenciation et mort cellulaires
Interactions cellulaires
Signalisation intracellulaire, transduction des signaux, biologie des récepteurs et des membranes
Biologie cellulaire
Microbiome
Microbiologie
Pharmacologie fondamentale
Publications
View all-
article Salarpour F, Sévigny J
P2Y2 Receptor Signaling in Health and Disease
Int J Mol Sci 26 (19), 2025.
-
article de Moraes JVB, Polêto MD, de Castro RB, Bressan GC, de S Vasconcellos R, Sévigny J, Fietto JR
Structural Modeling of NTPDase-Substrate Complexes Preserving Catalytic Experimental Features
ACS Omega 10 (38), 2025.
-
article Aftab H, Dutt SM, Mali SN, Vigiani E, Pelletier J, Sévigny J, Gurav SS, Jawarkar RD, Almalki AS, Akram MS, Batool Z, Schenone S, Iqbal J, Shafiq Z
Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 4-Propylsulfonylpiperazines-Based Thiosemicarbazones as Ecto-5-Nucleotidase and NTPDase Inhibitors
Arch Pharm (Weinheim) 358 (9), 2025.
Projects
- A recombinant soluble NTPDase8 as a novel biological treatment for inflammatory bowel disease, from 2021-10-01 to 2026-09-30
- Ectonucleotidases and Extracellular Nucleotides in Smooth Muscle Cell Contraction, from 2023-04-01 to 2028-03-31
- Regroupement Québécois de Recherche sur la Fonction, l’Ingénierie et les Applications des Protéines, from 2024-04-01 to 2030-03-31
- Initial biophysical analysis of the NTPDase3 antibody binding site to NTPDase3 and preparation of antibodies, from 2025-07-22 to 2026-07-21
- Development and characterization of K. PHAFFII apyrases for research and inflammation control, from 2025-04-01 to 2026-03-31
- Novel P2Y6 antagonists as a potential therapy for inflammatory bowel disease, from 2021-07-01 to 2025-06-30
- Scaling up the production of recombinant human NTPDase8 in CHO expression system for in vivo testing, from 2023-09-01 to 2024-03-31